Regenxbio Signs an Exclusive Development and Commercialization Agreement with Neurimmune for AAV Gene Therapies Targeting Neurodegenerative Diseases

Regenxbio Signs an Exclusive Development and Commercialization Agreement with Neurimmune for AAV Gene Therapies Targeting Neurodegenerative Diseases

Shots:

  • Regenxbio and Neurimmune enter into a collaboration to develop vectorized Ab by combining antibodies identified using Neurimmune’s reverse translational medicine platform with Regenxbio’s NAV technology platform for chronic neuro-degenerative diseases including tauopathies
  • The companies will jointly develop & commercialize AVV gene therapies with equal development cost-sharing with an initial focus on tauopathies. Following initial research, each company has an option to co-develop & co-commercialize each target or to elect to receive royalties in lieu of each target
  • Neurimmune’s RTM technology translates the genetic information from human’s WBC into selective Abs. Regenxbio’s technology involves the development of one-time treatments in multiple disease areas based on AAV-mediated AB delivery using NAV Vectors used to treat chronic diseases

Click here to­ read full press release/article | Ref: Regenxbio | Image: Neurimmune